Agios Pharmaceuticals Inc (AGIO) 131.55 $AGIO
Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration
GlobeNewswire - 39 mins ago
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that its collaboration partner Celgene Corporation has agreed that it will exercise its option to obtain an exclusive license outside the United States for AG-120, a first-in-class, oral, potent inhibitor of the mutant IDH1 protein under the terms of the 2010 collaboration agreement. This would be the second IDH mutant inhibitor to be licensed by Celgene in less than a year. AG-120 is currently being evaluated in two Phase 1 dose escalation trials, one in advanced hematologic malignancies and the other in advanced solid tumors. Both trials are evaluating AG-120 in patients whose cancer harbors an IDH1 mutation. The first data from the AG-120 program were presented at the EORTC-NCI-AACR Symposium on November 19, 2014 in advanced hematologic malignancies. Agios expects to report the first data from the Phase 1 advanced solid tumor trial at a medical conference in 2015. Celgene's exercise of the option is subject to receipt of any required regulatory approvals including any applicable clearance under the Hart-Scott-Rodino Act. Agios is webcasting its corporate presentation from the 33 Annual J.P. Morgan Healthcare Conference today at 2:30 p.m. PST (5:30 p.m. EST). The presentation will be followed by a webcast of its question and answer session at 3:00 p.m. PST (6:00 p.m. EST).
JPM: 58.83 (-0.51), AGIO: 131.55 (+3.43), CELGZ: 3.41 (+0.13)
Value Investing Strategy For Biotech
Henry Wolfe - at Seeking Alpha - Mon Jan 12, 11:57AM CST
CARA: 10.99 (+0.04), BLCM: 31.33 (-0.42), GILD: 101.21 (-1.00), KITE: 82.35 (+3.21), CLDX: 19.03 (-0.08), CALA: 22.86 (-0.78), AGIO: 131.55 (+3.43)
Why Agios Pharmaceuticals (AGIO) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 7:35AM CST
Agios Pharmaceuticals has decent short-term momentum and it is seeing solid activity on the earnings estimate revision front as well.
AGIO: 131.55 (+3.43)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 101.95 (-1.68), ACT: 272.28 (+3.60), AMGN: 156.22 (+0.49), RGLS: 18.90 (-0.43), EPZM: 17.49 (+0.01), ALKS: 68.61 (+3.47), HSP: 61.55 (-0.09), CELG: 117.00 (+3.33), JNJ: 104.58 (-0.36), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), ACHN: 14.64 (+0.08), MRK: 62.30 (-0.26), ABBV: 65.76 (-0.02), AGIO: 131.55 (+3.43), XLRN: 40.89 (-0.25), NVS: 95.48 (-0.64)
The Surprising Thing Most of 2014's Top 10 Stocks Have in Common
Keith Speights, The Motley Fool - Motley Fool - Sun Jan 11, 9:03AM CST
Are you good at spotting patterns? Most of us are. We even spot patterns when they're really not there -- like seeing faces in clouds. The list below of 2014's top 10 stocks with a market cap above $300 million, however, reveals a very real pattern...
AVNR: 16.96 (unch), NPSP: 45.35 (+3.44), AGIO: 131.55 (+3.43), CELG: 117.00 (+3.33), EXEL: 1.65 (-0.11)
'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab
at The Street - Fri Jan 09, 1:56PM CST
Following a week of awareness raising through phone calls, Twitter and a Loncar guest appearance on CNBC, the number of JPM breakout session webcasts has increased significantly.
BLUE: 101.95 (-1.68), BIIB: 347.84 (+5.50), JUNO: 61.51 (+7.24), AGIO: 131.55 (+3.43), CELG: 117.00 (+3.33)
InsiderInsights.com Daily Round Up 1/6/15: XOMA, CODI, MNST, BBY
InsiderInsights - at Seeking Alpha - Thu Jan 08, 9:37AM CST
MNST: 111.96 (-5.08), CODI: 17.00 (+0.08), MILL: 1.02 (-0.03), NRX: 7.90 (-1.19), BBY: 39.09 (+1.03), FUND: 7.23 (-0.05), LVS: 55.01 (-0.10), SPB: 96.97 (+0.59), QVCA: 28.48 (+0.10), LMCA: 35.22 (+0.27), BGH: 20.84 (+0.35), SIX: 43.72 (+0.42), AGIO: 131.55 (+3.43), XOMA: 3.73 (+0.07), JGV: 12.49 (-0.10)
3 Biotech Stocks That Could Trounce Gilead Sciences, Inc. in 2015
Motley Fool Staff - Motley Fool - Wed Jan 07, 8:03AM CST
Sovaldi pill. Source: Gilead Sciences Gilead Sciences had another phenomenal year in 2014, returning 26% for investors. That's more than double the return of the broad-based S&P 500 , and it has hepatitis C drug Sovaldi to thank. In...
BLUE: 101.95 (-1.68), BIIB: 347.84 (+5.50), GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), AGIO: 131.55 (+3.43), ABBV: 65.76 (-0.02), EXEL: 1.65 (-0.11), CELG: 117.00 (+3.33)
Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains
at The Street - Tue Jan 06, 7:25PM CST
The markets are presenting a buying opportunity at current levels, but only if you know which stocks to buy, Cramer says.
TSLA: 202.21 (-4.45), GE: 23.98 (-0.05), OVAS: 49.24 (-0.92), NMM: 12.41 (+0.12), XOM: 90.33 (-1.77), T: 33.49 (+0.09), ESPR: 48.52 (+3.58), IBM: 156.44 (-2.67), IRE: 14.01 (-0.12), DTV: 84.72 (-0.66), PTCT: 53.70 (+0.08), RCPT: 120.88 (-3.63), TEG: 77.50 (-0.53), PPG: 226.25 (-0.72), WAG: 76.05 (-0.49), BLUE: 101.95 (-1.68), TGTX: 15.98 (-0.88), WFC: 52.05 (-0.63), BA: 130.87 (-0.67), RAD: 7.79 (-0.04), ISIS: 73.34 (+1.08), RNA: 18.77 (+0.01), ACHN: 14.64 (+0.08), JCP: 8.14 (+0.23), CVS: 97.20 (-0.72), MCD: 93.01 (-0.20), AGIO: 131.55 (+3.43), CVX: 105.88 (-2.33), VZ: 47.08 (+0.32), FOLD: 8.88 (+0.04)
Public Shame for Biotechs Not Webcasting 'JPM15' Breakout Sessions
at The Street - Tue Jan 06, 2:08PM CST
In a blow to investor transparency, an embarrassingly small number of healthcare companies are webcasting their Q&A breakout sessions at next week's J.P. Morgan Healthcare Conference.
BLUE: 101.95 (-1.68), BIIB: 347.84 (+5.50), VRTX: 118.31 (-3.90), ISIS: 73.34 (+1.08), SGEN: 32.03 (+1.48), GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), AGIO: 131.55 (+3.43), BMY: 62.18 (+1.86), CELG: 117.00 (+3.33)
Jim Cramer: Why Are You Shorting Innovative Biotech Stocks?
at The Street - Tue Jan 06, 10:37AM CST
Cramer says investors shouldn't short-sell biotechs because they are innovators. Look at Alkermes' latest success with treating depression.
GILD: 101.21 (-1.00), AGIO: 131.55 (+3.43), CVX: 105.88 (-2.33), ALKS: 68.61 (+3.47), REGN: 413.33 (+2.29)
Biotechs to Follow in 2015 off Fresh Insider Moves
ACCESSWIRE - Tue Jan 06, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2015 / Insider moves are always interesting to equity traders no matter where they occur, but more than any other sector, insider buys tend to inspire the most chatter around biotech. This is mostly due to the esoteric science and trial statistics that often determine the fate of a firm, which company and other biotech insiders tend to know more about than even premium hedge fund operators.
ADXS: 12.09 (+0.79), SGEN: 32.03 (+1.48), GILD: 101.21 (-1.00), OPK: 10.27 (+0.17), MRK: 62.30 (-0.26), IBB: 315.06 (+1.74), AGIO: 131.55 (+3.43), TEVA: 57.01 (+0.29), CELG: 117.00 (+3.33)
Agios Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12
GlobeNewswire - Mon Jan 05, 3:39PM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the company will webcast its corporate presentation from the 33 Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2015 at 2:30 p.m. PST (5:30 p.m. EST).
JPM: 58.83 (-0.51), AGIO: 131.55 (+3.43)
Should Celgene Corporation Be a Staple in Long-Term Portfolios?
Todd Campbell, The Motley Fool - Motley Fool - Mon Jan 05, 8:33AM CST
Source Celgene. Celgene 's latest outlook for the next few years projects that sales will roughly double between 2013 and 2017. If Celgene delivers on that rosy outlook, investors might find including this biotech in long-haul investment...
BLUE: 101.95 (-1.68), AGIO: 131.55 (+3.43), CELG: 117.00 (+3.33)
These 3 Biotech Stocks Tripled Investors' Money in 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 04, 11:32AM CST
Life-changing financial gains are usually generated over the long haul, not in one year. However, sometimes stocks can put up eye-popping returns over a short period of time and when they do they can have a huge impact on investor's portfolios. For...
BLUE: 101.95 (-1.68), OVAS: 49.24 (-0.92), AGIO: 131.55 (+3.43)
The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 101.95 (-1.68), TTPH: 39.27 (-3.99), AVNR: 16.96 (unch), SWKS: 72.32 (-1.76), CMRX: 40.00 (+1.09), ACHN: 14.64 (+0.08), HA: 24.22 (-0.91), RCPT: 120.88 (-3.63), PTCT: 53.70 (+0.08), AGIO: 131.55 (+3.43)
Biotech Stocks 2014: The Best, Worst and Fastest-Growing
at The Street - Fri Jan 02, 7:33AM CST
Once again, biotech stocks greatly outperformed the broader market in 2014.
BLUE: 101.95 (-1.68), OVAS: 49.24 (-0.92), ACHN: 14.64 (+0.08), RCPT: 120.88 (-3.63), AGIO: 131.55 (+3.43)
Bull of the Day: Incyte (INCY) - Bull of the Day
Kevin Cook - ZACKS - Fri Jan 02, 12:00AM CST
Bull of the Day: Incyte (INCY) - Bull of the Day
PCYC: 123.71 (-0.49), GILD: 101.21 (-1.00), SGEN: 32.03 (+1.48), INCY: 73.30 (+1.27), ABBV: 65.76 (-0.02), AGIO: 131.55 (+3.43)
These 3 Biotechs Are Looking at a Happy New Year
Todd Campbell, The Motley Fool - Motley Fool - Wed Dec 31, 11:33AM CST
This healthcare edition of Industry Focus takes a look at three biotech stocks and why each company is positioned for a great performance in the coming year. If your portfolio could use some exposure to healthcare and biotechs, join the Fool's...
NFLX: 318.83 (-10.46), MDVN: 104.39 (+0.90), JNJ: 104.58 (-0.36), AMZN: 291.41 (-5.52), JPM: 58.83 (-0.51), GILD: 101.21 (-1.00), AGIO: 131.55 (+3.43), AAPL: 109.25 (-2.76), XLRN: 40.89 (-0.25), CELG: 117.00 (+3.33)
Agios Announces that Celgene Has Agreed to Exercise its Option to License AG-120 under Global Strategic Collaboration
GlobeNewswire - 39 mins ago
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced that its collaboration partner Celgene Corporation has agreed that it will exercise its option to obtain an exclusive license outside the United States for AG-120, a first-in-class, oral, potent inhibitor of the mutant IDH1 protein under the terms of the 2010 collaboration agreement. This would be the second IDH mutant inhibitor to be licensed by Celgene in less than a year. AG-120 is currently being evaluated in two Phase 1 dose escalation trials, one in advanced hematologic malignancies and the other in advanced solid tumors. Both trials are evaluating AG-120 in patients whose cancer harbors an IDH1 mutation. The first data from the AG-120 program were presented at the EORTC-NCI-AACR Symposium on November 19, 2014 in advanced hematologic malignancies. Agios expects to report the first data from the Phase 1 advanced solid tumor trial at a medical conference in 2015. Celgene's exercise of the option is subject to receipt of any required regulatory approvals including any applicable clearance under the Hart-Scott-Rodino Act. Agios is webcasting its corporate presentation from the 33 Annual J.P. Morgan Healthcare Conference today at 2:30 p.m. PST (5:30 p.m. EST). The presentation will be followed by a webcast of its question and answer session at 3:00 p.m. PST (6:00 p.m. EST).
JPM: 58.83 (-0.51), AGIO: 131.55 (+3.43), CELGZ: 3.41 (+0.13)
Value Investing Strategy For Biotech
Henry Wolfe - at Seeking Alpha - Mon Jan 12, 11:57AM CST
CARA: 10.99 (+0.04), BLCM: 31.33 (-0.42), GILD: 101.21 (-1.00), KITE: 82.35 (+3.21), CLDX: 19.03 (-0.08), CALA: 22.86 (-0.78), AGIO: 131.55 (+3.43)
Why Agios Pharmaceuticals (AGIO) Could Be Positioned for a Surge? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 12, 7:35AM CST
Agios Pharmaceuticals has decent short-term momentum and it is seeing solid activity on the earnings estimate revision front as well.
AGIO: 131.55 (+3.43)
5 Predictions for Biotechnology Stocks in 2015
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 11, 10:02AM CST
Biotechnology was one of the market's shining stars in 2014. The Nasdaq Biotechnology Index ETF returned an impressive 33% last year, significantly outpacing the performance of the S&P 500. Of course, no one can know if biotechnology stocks will...
BLUE: 101.95 (-1.68), ACT: 272.28 (+3.60), AMGN: 156.22 (+0.49), RGLS: 18.90 (-0.43), EPZM: 17.49 (+0.01), ALKS: 68.61 (+3.47), HSP: 61.55 (-0.09), CELG: 117.00 (+3.33), JNJ: 104.58 (-0.36), ESRX: 83.08 (-1.82), GILD: 101.21 (-1.00), GWPH: 78.73 (+0.20), ACHN: 14.64 (+0.08), MRK: 62.30 (-0.26), ABBV: 65.76 (-0.02), AGIO: 131.55 (+3.43), XLRN: 40.89 (-0.25), NVS: 95.48 (-0.64)
The Surprising Thing Most of 2014's Top 10 Stocks Have in Common
Keith Speights, The Motley Fool - Motley Fool - Sun Jan 11, 9:03AM CST
Are you good at spotting patterns? Most of us are. We even spot patterns when they're really not there -- like seeing faces in clouds. The list below of 2014's top 10 stocks with a market cap above $300 million, however, reveals a very real pattern...
AVNR: 16.96 (unch), NPSP: 45.35 (+3.44), AGIO: 131.55 (+3.43), CELG: 117.00 (+3.33), EXEL: 1.65 (-0.11)
'Free the Webcast!' Investor Transparency Gains Momentum at 'JPM15' Healthcare Confab
at The Street - Fri Jan 09, 1:56PM CST
Following a week of awareness raising through phone calls, Twitter and a Loncar guest appearance on CNBC, the number of JPM breakout session webcasts has increased significantly.
BLUE: 101.95 (-1.68), BIIB: 347.84 (+5.50), JUNO: 61.51 (+7.24), AGIO: 131.55 (+3.43), CELG: 117.00 (+3.33)
InsiderInsights.com Daily Round Up 1/6/15: XOMA, CODI, MNST, BBY
InsiderInsights - at Seeking Alpha - Thu Jan 08, 9:37AM CST
MNST: 111.96 (-5.08), CODI: 17.00 (+0.08), MILL: 1.02 (-0.03), NRX: 7.90 (-1.19), BBY: 39.09 (+1.03), FUND: 7.23 (-0.05), LVS: 55.01 (-0.10), SPB: 96.97 (+0.59), QVCA: 28.48 (+0.10), LMCA: 35.22 (+0.27), BGH: 20.84 (+0.35), SIX: 43.72 (+0.42), AGIO: 131.55 (+3.43), XOMA: 3.73 (+0.07), JGV: 12.49 (-0.10)
3 Biotech Stocks That Could Trounce Gilead Sciences, Inc. in 2015
Motley Fool Staff - Motley Fool - Wed Jan 07, 8:03AM CST
Sovaldi pill. Source: Gilead Sciences Gilead Sciences had another phenomenal year in 2014, returning 26% for investors. That's more than double the return of the broad-based S&P 500 , and it has hepatitis C drug Sovaldi to thank. In...
BLUE: 101.95 (-1.68), BIIB: 347.84 (+5.50), GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), AGIO: 131.55 (+3.43), ABBV: 65.76 (-0.02), EXEL: 1.65 (-0.11), CELG: 117.00 (+3.33)
Jim Cramer's 'Mad Money' Recap: Knowing Where to Look for Bargains
at The Street - Tue Jan 06, 7:25PM CST
The markets are presenting a buying opportunity at current levels, but only if you know which stocks to buy, Cramer says.
TSLA: 202.21 (-4.45), GE: 23.98 (-0.05), OVAS: 49.24 (-0.92), NMM: 12.41 (+0.12), XOM: 90.33 (-1.77), T: 33.49 (+0.09), ESPR: 48.52 (+3.58), IBM: 156.44 (-2.67), IRE: 14.01 (-0.12), DTV: 84.72 (-0.66), PTCT: 53.70 (+0.08), RCPT: 120.88 (-3.63), TEG: 77.50 (-0.53), PPG: 226.25 (-0.72), WAG: 76.05 (-0.49), BLUE: 101.95 (-1.68), TGTX: 15.98 (-0.88), WFC: 52.05 (-0.63), BA: 130.87 (-0.67), RAD: 7.79 (-0.04), ISIS: 73.34 (+1.08), RNA: 18.77 (+0.01), ACHN: 14.64 (+0.08), JCP: 8.14 (+0.23), CVS: 97.20 (-0.72), MCD: 93.01 (-0.20), AGIO: 131.55 (+3.43), CVX: 105.88 (-2.33), VZ: 47.08 (+0.32), FOLD: 8.88 (+0.04)
Public Shame for Biotechs Not Webcasting 'JPM15' Breakout Sessions
at The Street - Tue Jan 06, 2:08PM CST
In a blow to investor transparency, an embarrassingly small number of healthcare companies are webcasting their Q&A breakout sessions at next week's J.P. Morgan Healthcare Conference.
BLUE: 101.95 (-1.68), BIIB: 347.84 (+5.50), VRTX: 118.31 (-3.90), ISIS: 73.34 (+1.08), SGEN: 32.03 (+1.48), GILD: 101.21 (-1.00), AMGN: 156.22 (+0.49), AGIO: 131.55 (+3.43), BMY: 62.18 (+1.86), CELG: 117.00 (+3.33)
Jim Cramer: Why Are You Shorting Innovative Biotech Stocks?
at The Street - Tue Jan 06, 10:37AM CST
Cramer says investors shouldn't short-sell biotechs because they are innovators. Look at Alkermes' latest success with treating depression.
GILD: 101.21 (-1.00), AGIO: 131.55 (+3.43), CVX: 105.88 (-2.33), ALKS: 68.61 (+3.47), REGN: 413.33 (+2.29)
Biotechs to Follow in 2015 off Fresh Insider Moves
ACCESSWIRE - Tue Jan 06, 9:00AM CST
NEW YORK, NY / ACCESSWIRE / January 6, 2015 / Insider moves are always interesting to equity traders no matter where they occur, but more than any other sector, insider buys tend to inspire the most chatter around biotech. This is mostly due to the esoteric science and trial statistics that often determine the fate of a firm, which company and other biotech insiders tend to know more about than even premium hedge fund operators.
ADXS: 12.09 (+0.79), SGEN: 32.03 (+1.48), GILD: 101.21 (-1.00), OPK: 10.27 (+0.17), MRK: 62.30 (-0.26), IBB: 315.06 (+1.74), AGIO: 131.55 (+3.43), TEVA: 57.01 (+0.29), CELG: 117.00 (+3.33)
Agios Pharmaceuticals to Present at the 33rd Annual J.P. Morgan Healthcare Conference on Monday, January 12
GlobeNewswire - Mon Jan 05, 3:39PM CST
Agios Pharmaceuticals, Inc. (Nasdaq:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, today announced the company will webcast its corporate presentation from the 33 Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 12, 2015 at 2:30 p.m. PST (5:30 p.m. EST).
JPM: 58.83 (-0.51), AGIO: 131.55 (+3.43)
Should Celgene Corporation Be a Staple in Long-Term Portfolios?
Todd Campbell, The Motley Fool - Motley Fool - Mon Jan 05, 8:33AM CST
Source Celgene. Celgene 's latest outlook for the next few years projects that sales will roughly double between 2013 and 2017. If Celgene delivers on that rosy outlook, investors might find including this biotech in long-haul investment...
BLUE: 101.95 (-1.68), AGIO: 131.55 (+3.43), CELG: 117.00 (+3.33)
These 3 Biotech Stocks Tripled Investors' Money in 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Jan 04, 11:32AM CST
Life-changing financial gains are usually generated over the long haul, not in one year. However, sometimes stocks can put up eye-popping returns over a short period of time and when they do they can have a huge impact on investor's portfolios. For...
BLUE: 101.95 (-1.68), OVAS: 49.24 (-0.92), AGIO: 131.55 (+3.43)
The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 101.95 (-1.68), TTPH: 39.27 (-3.99), AVNR: 16.96 (unch), SWKS: 72.32 (-1.76), CMRX: 40.00 (+1.09), ACHN: 14.64 (+0.08), HA: 24.22 (-0.91), RCPT: 120.88 (-3.63), PTCT: 53.70 (+0.08), AGIO: 131.55 (+3.43)
Biotech Stocks 2014: The Best, Worst and Fastest-Growing
at The Street - Fri Jan 02, 7:33AM CST
Once again, biotech stocks greatly outperformed the broader market in 2014.
BLUE: 101.95 (-1.68), OVAS: 49.24 (-0.92), ACHN: 14.64 (+0.08), RCPT: 120.88 (-3.63), AGIO: 131.55 (+3.43)
Bull of the Day: Incyte (INCY) - Bull of the Day
Kevin Cook - ZACKS - Fri Jan 02, 12:00AM CST
Bull of the Day: Incyte (INCY) - Bull of the Day
PCYC: 123.71 (-0.49), GILD: 101.21 (-1.00), SGEN: 32.03 (+1.48), INCY: 73.30 (+1.27), ABBV: 65.76 (-0.02), AGIO: 131.55 (+3.43)
These 3 Biotechs Are Looking at a Happy New Year
Todd Campbell, The Motley Fool - Motley Fool - Wed Dec 31, 11:33AM CST
This healthcare edition of Industry Focus takes a look at three biotech stocks and why each company is positioned for a great performance in the coming year. If your portfolio could use some exposure to healthcare and biotechs, join the Fool's...
NFLX: 318.83 (-10.46), MDVN: 104.39 (+0.90), JNJ: 104.58 (-0.36), AMZN: 291.41 (-5.52), JPM: 58.83 (-0.51), GILD: 101.21 (-1.00), AGIO: 131.55 (+3.43), AAPL: 109.25 (-2.76), XLRN: 40.89 (-0.25), CELG: 117.00 (+3.33)
